Do DHEA/DHEAS play a protective role in coronary heart disease?
- PMID: 10984071
Do DHEA/DHEAS play a protective role in coronary heart disease?
Abstract
Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulfate (DHEAS), the major androgens secreted by human adrenal glands, were suggested to play a protective role in the pathogenesis of atherosclerosis and coronary heart disease. On the basis of a critical review of all existing studies we concluded that 1) there is no evidence of a protective role of DHEA and DHEAS in women, and 2) men with low plasma DHEA and DHEAS levels can be considered as beings at risk of developing a fatal cardiovascular event. These androgens can interfere with atherogenic process by several mechanisms. They influence enzymes such as glucoso-6-phosphate dehydrogenase, which can modify the lipid spectrum. Furthermore, they can inhibit human platelet aggregation, enhance fibrinolysis, slow down cell proliferation and reduce plasma levels of plasminogen activator inhibitor type 1 and tissue plasminogen activator antigen. We suggest that all these DHEA(S) actions are dependent on sex hormone metabolic pathways. There are still insufficient data to advise DHEA supplementation in elderly men, but this type of hormone replacement therapy merits further studies.
Similar articles
-
Dehydroepiandrosterone, dehydroepiandrosterone sulphate and cardiovascular disease.J Endocrinol. 1996 Sep;150 Suppl:S149-53. J Endocrinol. 1996. PMID: 8943798 Review.
-
Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.Gynecol Endocrinol. 2000 Oct;14(5):342-63. doi: 10.3109/09513590009167703. Gynecol Endocrinol. 2000. PMID: 11109974 Clinical Trial.
-
Sexual dimorphism in the influence of advanced aging on adrenal hormone levels: the Rancho Bernardo Study.J Clin Endocrinol Metab. 2000 Oct;85(10):3561-8. doi: 10.1210/jcem.85.10.6861. J Clin Endocrinol Metab. 2000. PMID: 11061502 Clinical Trial.
-
Dehydroepiandrosterone and its sulfate predict the 5-year risk of coronary heart disease events in elderly men.J Am Coll Cardiol. 2014 Oct 28;64(17):1801-10. doi: 10.1016/j.jacc.2014.05.076. Epub 2014 Oct 21. J Am Coll Cardiol. 2014. PMID: 25443702
-
[Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulphate (DHEAS) in men with coronary artery disease].Pol Arch Med Wewn. 2004 Jun;111(6):769-75. Pol Arch Med Wewn. 2004. PMID: 15508802 Review. Polish. No abstract available.
Cited by
-
Dehydroepiandrosterone anti-atherogenesis effect is not via its conversion to estrogen.Acta Pharmacol Sin. 2009 Jan;30(1):42-53. doi: 10.1038/aps.2008.2. Epub 2008 Dec 8. Acta Pharmacol Sin. 2009. PMID: 19060916 Free PMC article.
-
Involvement of RhoA/Rho kinase signaling in protection against monocrotaline-induced pulmonary hypertension in pneumonectomized rats by dehydroepiandrosterone.Am J Physiol Lung Cell Mol Physiol. 2008 Jul;295(1):L71-8. doi: 10.1152/ajplung.90251.2008. Epub 2008 May 9. Am J Physiol Lung Cell Mol Physiol. 2008. PMID: 18469113 Free PMC article.
-
Neuroprotective properties of dehydroepiandrosterone-sulfate and its relationship to interleukin 6 after aneurysmal subarachnoid hemorrhage: a prospective cohort study.Crit Care. 2015 May 21;19(1):231. doi: 10.1186/s13054-015-0954-1. Crit Care. 2015. PMID: 25993987 Free PMC article.
-
Synergistic effects of dehydroepiandrosterone and retinoic acid on granulocytic differentiation of human promyelocytic NB4 cells.Int J Hematol. 2005 Jan;81(1):32-8. doi: 10.1532/ijh97.04117. Int J Hematol. 2005. PMID: 15717686
-
Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension.Cardiovasc Res. 2007 Jun 1;74(3):377-87. doi: 10.1016/j.cardiores.2007.01.021. Epub 2007 Feb 12. Cardiovasc Res. 2007. PMID: 17346686 Free PMC article.
